Shots: ProMab Biotechnologies signs WW license agreement with NantKwest to develop Ab targeting B-Cell Maturation Antigen (BCMA) against myeloma ProMab Biotechnologies get an option to add five chimeric antigen receptor […]readmore
Tags : NantKwest